Setipiprant
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
primaryTopic
Setipiprant
Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.
has abstract
Setipiprant (INN) (development ...... n be conducted fairly quickly.
@en
ATC prefix
CAS number
866460-33-5
FDA UNII code
BHF20LA2GM
IUPAC name
2-[8-Fluoro-2-(naphthalene-1-carbonyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl]acetic acid
@en
PubChem
thumbnail
Wikipage page ID
47,626,347
Wikipage revision ID
736,446,386
ChemSpiderID
29,738,718
legal status
Investigational
molecular weight
4.02417e+2
routes of administration
smiles
c15ccccc5cccc1CNCc2c3ncc2cc4F
StdInChIKey
IHAXLPDVOWLUOS-UHFFFAOYSA-N
hypernym
comment
Setipiprant (INN) (development ...... velopment in this application.
@en
label
Setipiprant
@en